ArticleThe American journal of pathology2012
Increased smooth muscle contractility in mice deficient for neuropilin 2.
Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Single-cell transcriptomic profiling of the neonatal oviduct and uterus reveals new insights into upper Müllerian duct regionalization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction.Cell communication and signaling : CCS · 2024Article
- Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction.bioRxiv : the preprint server for biology · 2023Article
- Emerging Roles for Neuropilin-2 in Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis.In vitro cellular & developmental biology. Animal · 2019Article
- Guidance Molecules in Vascular Smooth Muscle.Frontiers in physiology · 2018Review
- Regulation of TGF-β-mediated endothelial-mesenchymal transition by microRNA-27.Journal of biochemistry · 2017Article
- Deletion of neuropilin 2 enhances detrusor contractility following bladder outlet obstruction.JCI insight · 2017Article
- Human airway smooth muscle cell proliferation from asthmatics is negatively regulated by semaphorin3A.Oncotarget · 2016Article
- Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency.The American journal of pathology · 2016Article
- Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.Scientific reports · 2015Article
- Urinary Retention, Incontinence, and Dysregulation of Muscarinic Receptors in Male Mice Lacking Mras.PloS one · 2015Article
- Neuropilin 1 is essential for gastrointestinal smooth muscle contractility and motility in aged mice.PloS one · 2015Article
- Lymphangiogenesis and metastasis--a closer look at the neuropilin/semaphorin3 axis.Microvascular research · 2014Review
- Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regeneration.Pathology · 2014Article
- Neuropilin 1 expression correlates with differentiation status of epidermal cells and cutaneous squamous cell carcinomas.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- Symphony of vascular contraction: how smooth muscle cells lose harmony to signal increased vascular resistance in hypertension.Hypertension (Dallas, Tex. : 1979) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
Abstract
Neuropilins (NRPs) are transmembrane receptors that bind class 3 semaphorins and VEGF family members to regulate axon guidance and angiogenesis. Although expression of NRP1 by vascular smooth muscle cells (SMCs) has been reported, NRP function in smooth muscle (SM) in vivo is unexplored. Using Nrp2(+/LacZ) and Nrp2(+/gfp) transgenic mice, we observed robust and sustained expression of Nrp2 in the SM compartments of the bladder and gut, but no expression in vascular SM, skeletal muscle, or cardiac muscle. This expression pattern was recapitulated in vitro using primary human SM cell lines. Alterations in cell morphology after treatment of primary visceral SMCs with the NRP2 ligand semaphorin-3F (SEMA3F) were accompanied by inhibition of RhoA activity and myosin light chain phosphorylation, as well as decreased cytoskeletal stiffness. Ex vivo contractility testing of bladder muscle strips exposed to electrical stimulation or soluble agonists revealed enhanced tension generation of tissues from mice with constitutive or SM-specific knockout of Nrp2, compared with controls. Mice lacking Nrp2 also displayed increased bladder filling pressures, as assessed by cystometry in conscious mice. Together, these findings identify Nrp2 as a mediator of prorelaxant stimuli in SMCs and suggest a novel function for Nrp2 as a regulator of visceral SM contractility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.